FAQ on Quantum BioPharma Ltd.'s Completion of Dosing in Key Toxicity Studies for MS Drug Candidate

What is Quantum BioPharma Ltd.’s latest announcement about?

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its lead candidate, Lucid-21-302, a novel treatment for multiple sclerosis, supporting an upcoming IND application to the U.S. FDA.

Why is the completion of dosing in these studies significant?

This milestone is a major step towards submitting an Investigational New Drug (IND) application to the U.S. FDA by year-end and launching a Phase 2 clinical trial, positioning Lucid-21-302 as a potential first-in-class therapy for MS.

How does Lucid-21-302 work?

Lucid-21-302 is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Who is involved in the development of Lucid-21-302?

Quantum BioPharma Ltd., through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-21-302.

When is the IND application to the U.S. FDA expected?

The IND application is expected by year-end, following the completion of the 90-day oral toxicity and toxicokinetic studies.

Where can I find more information about Quantum BioPharma Ltd.?

More information is available in the company’s newsroom at https://ibn.fm/QNTM and the full press release at https://ibn.fm/euapt.

What are the implications of this development for MS patients?

The development of Lucid-21-302 offers hope for a first-in-class therapy that could prevent and reverse myelin degradation, addressing the root cause of multiple sclerosis.

How does Quantum BioPharma Ltd. plan to advance Lucid-21-302?

Following the IND application, Quantum BioPharma Ltd. aims to launch a Phase 2 clinical trial to further evaluate the safety and efficacy of Lucid-21-302 in treating multiple sclerosis.

What other projects is Quantum BioPharma Ltd. involved in?

Quantum BioPharma is also involved in developing treatments for neurodegenerative and metabolic disorders, alcohol misuse disorders, and maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc.